Renishaw Diagnostics Limited (RDL) is a world leading provider of trace level detection systems and is about to launch a novel, multiplex assay system, initially for research use but, once regulatory approvals are granted, for diagnosis of a range of human diseases.

Avian were appointed to help prepare for the international launch of the first of its products, branded RenDx™, based on a specialist type of spectroscopy known as SERRS. RDL’s business goal is to be a global player in the field of molecular diagnostics for human infectious diseases.

Dr Jim Greaves, Head of Marketing, said “I am delighted to be working with Avian who were the clear winners of the multi agency pitch. At RDL, we have a strong multi-disciplinary technical team and proven commercial skills so I’m looking forward to the successful launch of our research and clinical diagnostics products planned for the next few years.”

“I am very excited by this new work,” said Scott McCallum, MD Avian. “Renishaw Diagnostics has a tremendous future and this type of brief to build brands and create a strong market place presence is exactly what Avian do best.”